Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia

Outcomes of intravesical Bacillus Calmette-Guerin in patients with non-muscle invasive bladder cancer: a retrospective study in Australia

IntroductionInduction intravesical Bacillus Calmette-Guerin (BCG) followed by maintenance after transurethral resection of bladder tumor, is the standard adjuvant therapy for high-risk non-muscle invasive bladder cancer (NMIBC). There is sparse evidence on the practice of intravesical BCG in Austral...

Full description

Bibliographic Details
Main Authors:	Chamodi Pillippu Hewa, Stephen Della-Fiorentina, Kayvan Haghighi, Wei Chua, Peey-Sei Kok
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-02-01
Series:	Frontiers in Urology
Subjects:	intravesical BCG NMIBC disease-free survival bladder cancer TURBT overall survival
Online Access:	https://www.frontiersin.org/articles/10.3389/fruro.2024.1309532/full

Similar Items

Instillation Strategies for Non-Muscle-Invasive Bladder Cancer in the Bacillus Calmette-Guerin Shortage Era: A Simple Solution for BCG Discontinuation
by: Lin PT, et al.
Published: (2022-11-01)

Preoperative serum apolipoprotein A-I levels predict long-term survival in non-muscle-invasive bladder cancer patients
by: Shang Z, et al.
Published: (2018-05-01)

Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder
by: Eric K. Diner, et al.
Published: (2004-10-01)

Late-onset granulomatous prostatitis following intravesical bacille Calmette-Guerin therapy: case report
by: Octavio Castillo Cádiz, et al.
Published: (2016-06-01)

Intravesical bacillus Calmette–Guérin-induced myopathy presenting as rhabdomyolysis: a case report
by: Chae Hun Lee, et al.
Published: (2023-10-01)

Bacillus Calmette-Guerin (BCG) infections following intravesical BCG immunotherapy: a systematic review protocol
by: Roberta Monardo, et al.
Published: (2025-01-01)

Impact of intravesical Bacillus Calmette-Guérin and chemotherapy on the bladder microbiome in patients with non-muscle invasive bladder cancer
by: Christopher James, et al.
Published: (2023-04-01)

Complete response to intravesical gemcitabine in non‐muscle invasive bladder cancer patient after BCG failure: A case report and literature review
by: Fouad Nahhat, et al.
Published: (2022-09-01)

Secondary Haemophagocytic Lymphohistiocytosis Syndrome (HLH) After Intravesical Instillation of Bacillus Calmette-Guérin (BCG): A Case Report and Review of the Literature
by: Konstantinos Manganas, et al.
Published: (2022-10-01)

Efficacy of intravesical gemcitabine instillation compared with intravesical Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer
by: Dong Ha Kim, et al.
Published: (2024-12-01)

Bacillus Calmette–Guérin in Immuno-Regulation of Alzheimer’s Disease
by: Benjamin Y. Klein, et al.
Published: (2022-06-01)

Optimal interval timing between transurethral resection of bladder tumors and Bacillus Calmette‐Guerin perfusion
by: Tao‐nong Cai, et al.
Published: (2023-12-01)

Combined Application of Nivolumab and Intravesical Bacillus Calmette-Guérin Led to Acute-Onset Type 1 Diabetes
by: Koichi Fujiu, et al.
Published: (2019-06-01)

Bacillus Calmette-Guérin Spondylodiscitis after Intravesical BCG Therapy: A Case Report
by: Akihito Kawai, et al.
Published: (2022-11-01)

Oncolytic and immunotherapeutic CG0070 adenovirus for high-risk bacillus calmette-guerin unresponsive bladder cancer
by: Evan Austin, et al.
Published: (2021-12-01)

Novel Therapeutic Strategies for BCG-unresponsive Non-muscle Invasive Bladder Cancer
by: Peng Zhang, et al.
Published: (2022-12-01)

Preoperative sarcopenia and systemic immune-inflammation index can predict response to intravesical Bacillus Calmette-Guerin instillation in patients with non-muscle invasive bladder cancer
by: Peng Liu, et al.
Published: (2022-10-01)

Peripheral Mechanisms Underlying Bacillus Calmette–Guerin-Induced Lower Urinary Tract Symptoms (LUTS)
by: Meera Elmasri, et al.
Published: (2024-11-01)

Does post-void residual urine volume affect potential recurrence risk for non-muscle invasive bladder cancer?
by: Mohammad Talal Al-Zubi, et al.
Published: (2022-10-01)

Efficacy and safety of a novel 450 nm blue diode laser versus plasmakinetic electrocautery for the transurethral resection of non-muscle invasive bladder cancer: The protocol and result of a multicenter randomized controlled trial
by: Kaijie Wu, et al.
Published: (2023-01-01)

Intravesical chemotherapy in BCG waiting period may prolong time to recurrence for high-risk NMIBC patients
by: Zhen Li, et al.
Published: (2025-02-01)

Thulium laser en bloc resection reduces recurrence rates in NMIBC patients with tumor diameters ≥3cm compared to transurethral resection: a non-randomized controlled study
by: Zhipeng Yao, et al.
Published: (2024-10-01)

Active Surveillance in Non-Muscle Invasive Bladder Cancer, the Potential Role of Biomarkers: A Systematic Review
by: Diego Parrao, et al.
Published: (2024-04-01)

Intravesical Gemcitabine versus Intravesical Bacillus Calmette–Guérin for the Treatment of Non-Muscle Invasive Bladder Cancer: An Evaluation of Efficacy and Toxicity
by: Thiru Prasanna, et al.
Published: (2017-11-01)

Penile lesion with inguinal adenopathy after intravesical Bacillus Calmette-Guerin instillation therapy
by: Guven Aslan, et al.
Published: (2013-01-01)

Bacillus Calmette-Guérin pneumonitis after intravesical instillation: Report of two cases and a review of the literature
by: Martina Spisarova, et al.
Published: (2024-06-01)

Hyperthermia intravesical chemotherapy acts as a promising alternative to bacillus Calmette–Guérin instillation in non-muscle-invasive bladder cancer: a network meta-analysis
by: Na Zeng, et al.
Published: (2023-05-01)

A case of disseminated M. bovis bacillus Calmette-Guérin (BCG) disease after one month of BCG bladder infusion therapy and analysis of 77 cases of suspected BCG infection in Japan, 2017–2022
by: Masashi Nishimura, et al.
Published: (2023-01-01)

Mycobacterium Bovis Spondylodiscitis: A Rare Complication of Intravesical Bacillus Calmette-Guérin Therapy
by: Frédéric Quatannens, et al.
Published: (2022-07-01)

Update on the Mechanism of Action of Intravesical BCG Therapy to Treat Non-Muscle-Invasive Bladder Cancer
by: Mohamad Abou Chakra, et al.
Published: (2024-08-01)

Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
by: Wei Shen Tan, et al.
Published: (2023-07-01)

Bladder Contracture – A Rare and Serious Side Effect of Intravesical Bacillus Calmette-Guérin Therapy
by: Cindy Garcia, et al.
Published: (2016-01-01)

Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
by: Jiwoong Yu, et al.
Published: (2023-11-01)

Incidental discovery of a case of renal tuberculoma after intravesical BCG treatment
by: Komi Hola Sikpa, et al.
Published: (2022-11-01)

Afebrile tuberculous prostatic abscess with rectal fistula after intravesical Bacillus Calmette‐Guérin immunotherapy
by: Tatsuhiro Sawada, et al.
Published: (2025-01-01)

Disfunción orgánica múltiple como complicación de la instilación intravesical de bacilo de Calmette-Guérin
by: Eduardo Moreira, et al.
Published: (2019-07-01)

Bacillus Calmette–Guérin Immunotherapy for Cancer
by: Fabíola Cardillo, et al.
Published: (2021-05-01)

Accelerated Bacille Calmette-Guérin reactions: More than meets the eye
by: Paola Villanueva, et al.
Published: (2024-07-01)

Drug‐induced interstitial pneumonia after intravesical Bacillus Calmette‐Guerin administration for bladder cancer with scleroderma
by: Fumie Yoshioka, et al.
Published: (2023-03-01)

Radiomics of Contrast-Enhanced Computed Tomography: A Potential Biomarker for Pretreatment Prediction of the Response to Bacillus Calmette-Guerin Immunotherapy in Non-Muscle-Invasive Bladder Cancer
by: Lei Ye, et al.
Published: (2022-02-01)